A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease

NCT07647614 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease (PD)

Interventions

DRUG: 60 milligrams of ENERGI-F705 Tablets
DRUG: Placebo tablets
DRUG: 120 milligrams of ENERGI-F705 Tablets

Sponsor

Energenesis Biomedical Co., Ltd.